Related Experiment Videos
Adherence to Sedative Weaning Opportunities and Length of Stay for Critically Ill Children
Taylor M Smith1,2, Franklin Ducatez1,2,3, Barbara Jo Achuff4,5
1Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts.
Insights
Pediatric intensive care unit (ICU) clinicians had low adherence to sedative weaning opportunities. Improving adherence to sedative weaning can shorten ICU and hospital stays and reduce sedative exposure in critically ill children.
Area of Science:
- Pediatric critical care medicine
- Pharmacology
- Clinical outcomes research
Background:
- Prolonged sedative exposure in pediatric intensive care units (PICUs) is linked to adverse outcomes like delirium, withdrawal, and neurodevelopmental impairment.
- Clinical guidelines advocate for timely sedative weaning, but adherence to these opportunities and its impact on patient outcomes remain unclear.
Purpose of the Study:
- To assess adherence to sedative weaning opportunities in pediatric ICUs.
- To examine the association between weaning adherence and clinical outcomes, including length of stay and sedative exposure.
Main Methods:
- A multicenter cohort study analyzed data from over 15,000 ICU encounters in pediatric academic medical centers.
- Weaning adherence was calculated as the percentage of identified weaning opportunities resulting in dose reduction or discontinuation.
- Multivariable regression models adjusted for patient and center-level factors to assess the association between weaning adherence and outcomes.
Main Results:
- Overall adherence to sedative weaning opportunities was low at 28%, with missed opportunities being common (72%).
- Higher weaning adherence was significantly associated with shorter ICU length of stay (–2.3 days per 10% increase) and hospital length of stay (–3.6 days per 10% increase).
- Increased adherence also correlated with reduced sedative infusion duration and lower cumulative exposure to opioids, benzodiazepines, and alpha-2 agonists.
Conclusions:
- Adherence to sedative weaning protocols in pediatric ICUs is suboptimal.
- Improving adherence to sedative weaning opportunities is independently associated with reduced length of stay and sedative exposure.
- Targeting weaning adherence presents a potential modifiable strategy to improve clinical outcomes for critically ill children.
Importance:
Prolonged sedative exposure in pediatric intensive care units (ICUs) is associated with adverse outcomes including delirium, withdrawal, and neurodevelopmental impairment. Clinical guidelines recommend timely weaning, but adherence to weaning opportunities and its association with clinical outcomes is unknown.
Objectives:
To evaluate adherence to sedative weaning opportunities and examine the association between weaning adherence and clinical outcomes among pediatric ICU patients.
Design, Setting, And Participants:
This multicenter cohort study included ICU patients at 4 pediatric academic medical centers admitted between January 1, 2011, and December 31, 2024, with greater than 48 hours of cumulative sedative infusion exposure. Data extraction and analyses were performed between February and November 2025. Neonatal ICU stays were excluded.
Exposure:
Weaning adherence, defined as the percentage of identified opportunities to wean from sedation that resulted in weaning actions (dose decreases or discontinuations), calculated at the ICU encounter level. An opportunity was defined as 0 or 1 as-needed doses of any sedative in a 12-hour period.
Main Outcomes And Measures:
The primary outcomes were ICU and hospital length of stay. Secondary outcomes included infusion duration and cumulative sedative dose of each drug class. Multivariable linear regression models adjusted for center, age, and sex examined associations between weaning adherence and outcomes.
Results:
The cohort included 15 747 ICU encounters from 12 737 patients (median age, 1.1 years [IQR, 0.2-6.5 years]; 56% of encounters among male patients). Median ICU length of stay was 13 days (IQR, 7-25 days) and median hospital length of stay was 26 days (IQR, 14-55 days). Among a median of 30 (IQR, 13-68) opportunities to wean per ICU encounter, overall adherence to weaning opportunities was 28% (IQR, 14%-49%), while missed weaning opportunities were common (median, 72%; IQR 51%-86%). Higher weaning adherence was associated with shorter median ICU length of stay (-2.3 days [IQR, -2.4 to -2.2 days] per 10% increase; P < .001) and shorter median total hospital length of stay (-3.6 days [IQR, -4.0 to -3.4 days] per 10% increase; P < .001). Higher weaning adherence was associated with shorter median sedative infusion duration for all sedative classes combined (-1.1 days [IQR, -1.2 to -1.0 days] per 10% increase in adherence; P < .001) and lower median cumulative exposure to opioids (-3.5 mg/kg [IQR, -3.8 to -3.2 mg/kg]; P < .001), benzodiazepines (-3.4 mg/kg [IQR, -3.8 to -3.0 mg/kg]; P < .001), and α2 agonists (-27.7 µg/kg [IQR, -30.2 to -25.3 µg/kg]; P < .001).
Conclusions And Relevance:
In this multicenter cohort, adherence to sedative weaning opportunities was low. Higher weaning adherence was independently associated with shorter ICU and hospital lengths of stay and reduced sedative exposure. Improving adherence to sedative weaning opportunities may represent a modifiable target for reducing length of stay and sedative exposure.
Related Concept Videos
Stages of General Anesthesia
Drug Dosing: Infants and Children
Endotracheal Tube Extubation
Procedure
Extubation removes the endotracheal tube (ETT) from the patient on mechanical ventilation. It requires a well-coordinated, multidisciplinary approach involving physicians, nurses, respiratory therapists, and other healthcare professionals.
Parenteral Anesthetics: Overview
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
CNS Depressants: Barbiturates and Benzodiazepines